Galectin-10 antibodies
The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
1. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises a combination of a heavy chain variable domain (VH) and a light chain variable domain (VL),
wherein the VH comprises the amino acid sequence of SEQ ID NO: 194, and the VL comprises the amino acid sequence of SEQ ID NO: 195.
2. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.
3. A kit comprising an antibody or antigen binding fragment according to claim 1 .
4. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises HCDR3 consisting of SEQ ID NO: 162; HCDR2 consisting of SEQ ID NO: 161; HCDR1 consisting of SEQ ID NO: 160; LCDR3 consisting of SEQ ID NO: 179; LCDR2 consisting of SEQ ID NO: 178; and LCDR1 consisting of SEQ ID NO: 177.
5. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 4 and at least one pharmaceutically acceptable carrier or excipient.
6. A kit comprising an antibody or antigen binding fragment according to claim 4 .
7. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment comprises a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the set of CDR sequences selected from the group consisting of:
(i) HCDR3 comprising or consisting of SEQ ID NO: 3; HCDR2 comprising or consisting of SEQ ID NO: 2; HCDR1 comprising or consisting of SEQ ID NO: 1; LCDR3 comprising or consisting of SEQ ID NO: 58; LCDR2 comprising or consisting of SEQ ID NO: 57; LCDR1 comprising or consisting of SEQ ID NO: 56;
(ii) HCDR3 comprising or consisting of SEQ ID NO: 6; HCDR2 comprising or consisting of SEQ ID NO: 5; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 61; LCDR2 comprising or consisting of SEQ ID NO: 60; LCDR1 comprising or consisting of SEQ ID NO: 59;
(iii) HCDR3 comprising or consisting of SEQ ID NO: 9; HCDR2 comprising or consisting of SEQ ID NO: 8; HCDR1 comprising or consisting of SEQ ID NO: 7; LCDR3 comprising or consisting of SEQ ID NO: 64; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 62;
(iv) HCDR3 comprising or consisting of SEQ ID NO: 12; HCDR2 comprising or consisting of SEQ ID NO: 11; HCDR1 comprising or consisting of SEQ ID NO: 10; LCDR3 comprising or consisting of SEQ ID NO: 67; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 65;
(v) HCDR3 comprising or consisting of SEQ ID NO: 15; HCDR2 comprising or consisting of SEQ ID NO: 14; HCDR1 comprising or consisting of SEQ ID NO: 13; LCDR3 comprising or consisting of SEQ ID NO: 70; LCDR2 comprising or consisting of SEQ ID NO: 69; LCDR1 comprising or consisting of SEQ ID NO: 68;
(vi) HCDR3 comprising or consisting of SEQ ID NO: 18; HCDR2 comprising or consisting of SEQ ID NO: 17; HCDR1 comprising or consisting of SEQ ID NO: 16; LCDR3 comprising or consisting of SEQ ID NO: 72; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 71;
(vii) HCDR3 comprising or consisting of SEQ ID NO: 20; HCDR2 comprising or consisting of SEQ ID NO: 19; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 75; LCDR2 comprising or consisting of SEQ ID NO: 74; LCDR1 comprising or consisting of SEQ ID NO: 73;
(viii) HCDR3 comprising or consisting of SEQ ID NO: 23; HCDR2 comprising or consisting of SEQ ID NO: 22; HCDR1 comprising or consisting of SEQ ID NO: 21; LCDR3 comprising or consisting of SEQ ID NO: 67; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 65;
(ix) HCDR3 comprising or consisting of SEQ ID NO: 25; HCDR2 comprising or consisting of SEQ ID NO: 24; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 78; LCDR2 comprising or consisting of SEQ ID NO: 77; LCDR1 comprising or consisting of SEQ ID NO: 76;
(x) HCDR3 comprising or consisting of SEQ ID NO: 28; HCDR2 comprising or consisting of SEQ ID NO: 27; HCDR1 comprising or consisting of SEQ ID NO: 26; LCDR3 comprising or consisting of SEQ ID NO: 67; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 79;
(xi) HCDR3 comprising or consisting of SEQ ID NO: 31; HCDR2 comprising or consisting of SEQ ID NO: 30; HCDR1 comprising or consisting of SEQ ID NO: 29; LCDR3 comprising or consisting of SEQ ID NO: 81; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 80;
(xii) HCDR3 comprising or consisting of SEQ ID NO: 33; HCDR2 comprising or consisting of SEQ ID NO: 32; HCDR1 comprising or consisting of SEQ ID NO: 1; LCDR3 comprising or consisting of SEQ ID NO: 84; LCDR2 comprising or consisting of SEQ ID NO: 83; LCDR1 comprising or consisting of SEQ ID NO: 82;
(xiii) HCDR3 comprising or consisting of SEQ ID NO: 36; HCDR2 comprising or consisting of SEQ ID NO: 35; HCDR1 comprising or consisting of SEQ ID NO: 34; LCDR3 comprising or consisting of SEQ ID NO: 87; LCDR2 comprising or consisting of SEQ ID NO: 86; LCDR1 comprising or consisting of SEQ ID NO: 85;
(xiv) HCDR3 comprising or consisting of SEQ ID NO: 38; HCDR2 comprising or consisting of SEQ ID NO: 11; HCDR1 comprising or consisting of SEQ ID NO: 37; LCDR3 comprising or consisting of SEQ ID NO: 78; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 88;
(xv) HCDR3 comprising or consisting of SEQ ID NO: 41; HCDR2 comprising or consisting of SEQ ID NO: 40; HCDR1 comprising or consisting of SEQ ID NO: 39; LCDR3 comprising or consisting of SEQ ID NO: 91; LCDR2 comprising or consisting of SEQ ID NO: 90; LCDR1 comprising or consisting of SEQ ID NO: 89;
(xvi) HCDR3 comprising or consisting of SEQ ID NO: 43; HCDR2 comprising or consisting of SEQ ID NO: 42; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 94; LCDR2 comprising or consisting of SEQ ID NO: 93; LCDR1 comprising or consisting of SEQ ID NO: 92;
(xvii) HCDR3 comprising or consisting of SEQ ID NO: 6; HCDR2 comprising or consisting of SEQ ID NO: 44; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 97; LCDR2 comprising or consisting of SEQ ID NO: 96; LCDR1 comprising or consisting of SEQ ID NO: 95;
(xviii) HCDR3 comprising or consisting of SEQ ID NO: 47; HCDR2 comprising or consisting of SEQ ID NO: 46; HCDR1 comprising or consisting of SEQ ID NO: 45; LCDR3 comprising or consisting of SEQ ID NO: 94; LCDR2 comprising or consisting of SEQ ID NO: 93; LCDR1 comprising or consisting of SEQ ID NO: 71;
(xix) HCDR3 comprising or consisting of SEQ ID NO: 50; HCDR2 comprising or consisting of SEQ ID NO: 49; HCDR1 comprising or consisting of SEQ ID NO: 48; LCDR3 comprising or consisting of SEQ ID NO: 96; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 95;
(xx) HCDR3 comprising or consisting of SEQ ID NO: 36; HCDR2 comprising or consisting of SEQ ID NO: 52; HCDR1 comprising or consisting of SEQ ID NO: 51; LCDR3 comprising or consisting of SEQ ID NO: 98; LCDR2 comprising or consisting of SEQ ID NO: 97; LCDR1 comprising or consisting of SEQ ID NO: 80; and
(xxi) HCDR3 comprising or consisting of SEQ ID NO: 55; HCDR2 comprising or consisting of SEQ ID NO: 54; HCDR1 comprising or consisting of SEQ ID NO: 53; LCDR3 comprising or consisting of SEQ ID NO: 81; LCDR2 comprising or consisting of SEQ ID NO: 93; LCDR1 comprising or consisting of SEQ ID NO: 71.
8. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 7 and at least one pharmaceutically acceptable carrier or excipient.
9. A kit comprising an antibody or antigen binding fragment according to claim 7 .
10. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises a combination of a heavy chain variable domain (VH) and a light chain variable domain (VL) selected from the following:
(i) a VH comprising the amino acid sequence of SEQ ID NO: 99 and a VL comprising the amino acid sequence of SEQ ID NO: 100;
(ii) a VH comprising the amino acid sequence of SEQ ID NO: 101 and a VL comprising the amino acid sequence of SEQ ID NO: 102;
(iii) a VH comprising the amino acid sequence of SEQ ID NO: 103 and a VL comprising the amino acid sequence of SEQ ID NO: 104;
(iv) a VH comprising the amino acid sequence of SEQ ID NO: 105 and a VL comprising the amino acid sequence of SEQ ID NO: 106;
(v) a VH comprising the amino acid sequence of SEQ ID NO: 107 and a VL comprising the amino acid sequence of SEQ ID NO: 108;
(vi) a VH comprising the amino acid sequence of SEQ ID NO: 109 and a VL comprising the amino acid sequence of SEQ ID NO: 110;
(vii) a VH comprising the amino acid sequence of SEQ ID NO: 111 and a VL comprising the amino acid sequence of SEQ ID NO: 112;
(viii) a VH comprising the amino acid sequence of SEQ ID NO: 113 and a VL comprising the amino acid sequence of SEQ ID NO: 114;
(ix) a VH comprising the amino acid sequence of SEQ ID NO: 115 and a VL comprising the amino acid sequence of SEQ ID NO: 116;
(x) a VH comprising the amino acid sequence of SEQ ID NO: 117 and a VL comprising the amino acid sequence of SEQ ID NO: 118;
(xi) a VH comprising the amino acid sequence of SEQ ID NO: 119 and a VL comprising the amino acid sequence of SEQ ID NO: 120;
(xii) a VH comprising the amino acid sequence of SEQ ID NO: 121 and a VL comprising the amino acid sequence of SEQ ID NO: 122;
(xiii) a VH comprising the amino acid sequence of SEQ ID NO: 123 and a VL comprising the amino acid sequence of SEQ ID NO: 124;
(xiv) a VH comprising the amino acid sequence of SEQ ID NO: 125 and a VL comprising the amino acid sequence of SEQ ID NO: 126;
(xv) a VH comprising the amino acid sequence of SEQ ID NO: 127 and a VL comprising the amino acid sequence of SEQ ID NO: 128;
(xvi) a VH comprising the amino acid sequence of SEQ ID NO: 129 and a VL comprising the amino acid sequence of SEQ ID NO: 130;
(xvii) a VH comprising the amino acid sequence of SEQ ID NO: 131 and a VL comprising the amino acid sequence of SEQ ID NO: 132;
(xviii) a VH comprising the amino acid sequence of SEQ ID NO: 133 and a VL comprising the amino acid sequence of SEQ ID NO: 134;
(xix) a VH comprising the amino acid sequence of SEQ ID NO: 135 and a VL comprising the amino acid sequence of SEQ ID NO: 136;
(xx) a VH comprising the amino acid sequence of SEQ ID NO: 137 and a VL comprising the amino acid sequence of SEQ ID NO: 138; and
(xxi) a VH comprising the amino acid sequence of SEQ ID NO: 139 and a VL comprising the amino acid sequence of SEQ ID NO: 140.
11. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 10 and at least one pharmaceutically acceptable carrier or excipient.
12. A kit comprising an antibody or antigen binding fragment according to claim 10 .
13. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment comprises a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the set of CDR sequences selected from the group consisting of:
(i) HCDR3 comprising or consisting of SEQ ID NO: 162; HCDR2 comprising or consisting of SEQ ID NO: 161; HCDR1 comprising or consisting of SEQ ID NO: 160; LCDR3 comprising or consisting of SEQ ID NO: 179; LCDR2 comprising or consisting of SEQ ID NO: 178; LCDR1 comprising or consisting of SEQ ID NO: 177;
(ii) HCDR3 comprising or consisting of SEQ ID NO: 165; HCDR2 comprising or consisting of SEQ ID NO: 164; HCDR1 comprising or consisting of SEQ ID NO: 163; LCDR3 comprising or consisting of SEQ ID NO: 182; LCDR2 comprising or consisting of SEQ ID NO: 181; LCDR1 comprising or consisting of SEQ ID NO: 180;
(iii) HCDR3 comprising or consisting of SEQ ID NO: 168; HCDR2 comprising or consisting of SEQ ID NO: 167; HCDR1 comprising or consisting of SEQ ID NO: 166; LCDR3 comprising or consisting of SEQ ID NO: 185; LCDR2 comprising or consisting of SEQ ID NO: 184; LCDR1 comprising or consisting of SEQ ID NO: 183;
(iv) HCDR3 comprising or consisting of SEQ ID NO: 171; HCDR2 comprising or consisting of SEQ ID NO: 170; HCDR1 comprising or consisting of SEQ ID NO: 169; LCDR3 comprising or consisting of SEQ ID NO: 187; LCDR2 comprising or consisting of SEQ ID NO: 186; LCDR1 comprising or consisting of SEQ ID NO: 180;
(v) HCDR3 comprising or consisting of SEQ ID NO: 174; HCDR2 comprising or consisting of SEQ ID NO: 173; HCDR1 comprising or consisting of SEQ ID NO: 172; LCDR3 comprising or consisting of SEQ ID NO: 189; LCDR2 comprising or consisting of SEQ ID NO: 188; LCDR1 comprising or consisting of SEQ ID NO: 180;
(vi) HCDR3 comprising or consisting of SEQ ID NO: 176; HCDR2 comprising or consisting of SEQ ID NO: 175; HCDR1 comprising or consisting of SEQ ID NO: 163; LCDR3 comprising or consisting of SEQ ID NO: 192; LCDR2 comprising or consisting of SEQ ID NO: 191; LCDR1 comprising or consisting of SEQ ID NO: 190; and
(vii) HCDR3 comprising or consisting of SEQ ID NO: 165; HCDR2 comprising or consisting of SEQ ID NO: 164; HCDR1 comprising or consisting of SEQ ID NO: 163; LCDR3 comprising or consisting of SEQ ID NO: 193; LCDR2 comprising or consisting of SEQ ID NO: 181; LCDR1 comprising or consisting of SEQ ID NO: 180.
14. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 13 and at least one pharmaceutically acceptable carrier or excipient.
15. A kit comprising an antibody or antigen binding fragment according to claim 13 .
16. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises a combination of a heavy chain variable domain (VH) and a light chain variable domain (VL) selected from the following:
(i) a VH comprising the amino acid sequence of SEQ ID NO: 194 and a VL comprising the amino acid sequence of SEQ ID NO: 195;
(ii) a VH comprising the amino acid sequence of SEQ ID NO: 196 and a VL comprising the amino acid sequence of SEQ ID NO: 197;
(iii) a VH comprising the amino acid sequence of SEQ ID NO: 198 and a VL comprising the amino acid sequence of SEQ ID NO: 199;
(iv) a VH comprising the amino acid sequence of SEQ ID NO: 200 and a VL comprising the amino acid sequence of SEQ ID NO: 201;
(v) a VH comprising the amino acid sequence of SEQ ID NO: 202 and a VL comprising the amino acid sequence of SEQ ID NO: 203;
(vi) a VH comprising the amino acid sequence of SEQ ID NO: 204 and a VL comprising the amino acid sequence of SEQ ID NO: 205; and
(vii) a VH comprising the amino acid sequence of SEQ ID NO: 206 and a VL comprising the amino acid sequence of SEQ ID NO: 207.
17. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 16 and at least one pharmaceutically acceptable carrier or excipient.
18. A kit comprising an antibody or antigen binding fragment according to claim 16 .
19. An antibody which binds to galectin-10, wherein the antibody comprises a VHH domain comprising the set of CDR sequences selected from the group consisting of:
(i) CDR3 comprising or consisting of SEQ ID NO: 210; CDR2 comprising or consisting of SEQ ID NO: 209; CDR1 comprising or consisting of SEQ ID NO: 208;
(ii) CDR3 comprising or consisting of SEQ ID NO: 213; CDR2 comprising or consisting of SEQ ID NO: 212; CDR1 comprising or consisting of SEQ ID NO: 211;
(iii) CDR3 comprising or consisting of SEQ ID NO: 216; CDR2 comprising or consisting of SEQ ID NO: 215; CDR1 comprising or consisting of SEQ ID NO: 214;
(iv) CDR3 comprising or consisting of SEQ ID NO: 219; CDR2 comprising or consisting of SEQ ID NO: 218; CDR1 comprising or consisting of SEQ ID NO: 217;
(v) CDR3 comprising or consisting of SEQ ID NO: 222; CDR2 comprising or consisting of SEQ ID NO: 221; CDR1 comprising or consisting of SEQ ID NO: 220;
(vi) CDR3 comprising or consisting of SEQ ID NO: 225; CDR2 comprising or consisting of SEQ ID NO: 224; CDR1 comprising or consisting of SEQ ID NO: 223;
(vii) CDR3 comprising or consisting of SEQ ID NO: 228; CDR2 comprising or consisting of SEQ ID NO: 227; CDR1 comprising or consisting of SEQ ID NO: 226;
(viii) CDR3 comprising or consisting of SEQ ID NO: 231; CDR2 comprising or consisting of SEQ ID NO: 230; CDR1 comprising or consisting of SEQ ID NO: 229;
(ix) CDR3 comprising or consisting of SEQ ID NO: 234; CDR2 comprising or consisting of SEQ ID NO: 233; CDR1 comprising or consisting of SEQ ID NO: 232;
(x) CDR3 comprising or consisting of SEQ ID NO: 236; CDR2 comprising or consisting of SEQ ID NO: 235; CDR1 comprising or consisting of SEQ ID NO: 226;
(xi) CDR3 comprising or consisting of SEQ ID NO: 238; CDR2 comprising or consisting of SEQ ID NO: 237; CDR1 comprising or consisting of SEQ ID NO: 232;
(xii) CDR3 comprising or consisting of SEQ ID NO: 241; CDR2 comprising or consisting of SEQ ID NO: 240; CDR1 comprising or consisting of SEQ ID NO: 239;
(xiii) CDR3 comprising or consisting of SEQ ID NO: 236; CDR2 comprising or consisting of SEQ ID NO: 235; CDR1 comprising or consisting of SEQ ID NO: 226;
(xiv) CDR3 comprising or consisting of SEQ ID NO: 244; CDR2 comprising or consisting of SEQ ID NO: 243; CDR1 comprising or consisting of SEQ ID NO: 242;
(xv) CDR3 comprising or consisting of SEQ ID NO: 234; CDR2 comprising or consisting of SEQ ID NO: 233; CDR1 comprising or consisting of SEQ ID NO: 232;
(xvi) CDR3 comprising or consisting of SEQ ID NO: 247; CDR2 comprising or consisting of SEQ ID NO: 246; CDR1 comprising or consisting of SEQ ID NO: 245; and
(xvii) CDR3 comprising or consisting of SEQ ID NO: 249; CDR2 comprising or consisting of SEQ ID NO: 248; CDR1 comprising or consisting of SEQ ID NO: 217.
20. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 19 and at least one pharmaceutically acceptable carrier or excipient.
21. A kit comprising an antibody or antigen binding fragment according to claim 19 .
22. An antibody which binds to galectin-10, wherein the antibody comprises a VHH domain and wherein the VHH domain comprises or consists of the amino acid sequence as set forth in any one of SEQ ID NOs: 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265 or 266.
23. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 22 and at least one pharmaceutically acceptable carrier or excipient.
24. A kit comprising an antibody or antigen binding fragment according to claim 22 .